Traws Pharma has received approval to proceed with Phase 2 studies for ratutrelvir, a ritonavir-free treatment for COVID-19.
The trials will assess safety, efficacy, disease rebound, and incidence of Long COVID compared to PAXLOVID®.
Top-line data from the trials is expected by year-end 2025.
Phase 2 Trials Initiated
Traws Pharma has initiated Phase 2 trials for ratutrelvir in COVID subjects, aiming for significant results by year-end 2025.
Comparison with PAXLOVID®
The study will compare ratutrelvir with PAXLOVID®, assessing safety and efficacy in COVID patients.
Potential Best-in-Class Agent
Ratutrelvir, a ritonavir-free agent, shows potential to become a new standard of care for COVID treatment.
- Traws Pharma's ratutrelvir has the potential to address shortcomings of current COVID treatments.
- The ritonavir-free profile of ratutrelvir allows for once-daily dosing, reducing the risk of disease rebound and Long COVID.
These Phase 2 trials mark a crucial step in evaluating the effectiveness of ratutrelvir against COVID-19, offering hope for improved treatments. Results expected by year-end 2025 will determine its future as a potential game-changer in COVID therapeutics.